Systemic Immune Inflammation Index as a Key Marker of Survival and Immune-related Adverse Events in Immune Checkpoint Inhibitor Therapy

Simple item page
dc.contributor.authorEkinci F.
dc.contributor.authorBalcik O.Y.
dc.contributor.authorDemir B.
dc.contributor.authorGursoy P.
dc.contributor.authorOzveren A.
dc.contributor.authorErdogan A.P.
dc.date.accessioned2024-07-22T08:04:18Z
dc.date.available2024-07-22T08:04:18Z
dc.date.issued2022
dc.description.abstractObjective: To evaluate the prognostic significance of the new index designed by formulating neutrophil, lymphocyte, and platelet counts in patients with metastatic disease receiving immune checkpoint inhibitors (ICI) and its effect on the immune-related adverse events (irAEs). Study Design: Cohort study. Place and Duration of Study: Department of Medical Oncology, University of Manisa Celal Bayar, University of Aydin Adnan Menderes, and University of Ege, and Izmir Kent Hospital, Turkey, from January 2016 to April 2020. Methodology: Patients with metastatic disease receiving ICI sufficient follow-up data were included. Patients, who had received treatment for a minimum of 3 months, were evaluated for the response. Systemic immune-inflammation index (SII) was calculated as neutrophil (/L) × (lymphocyte (/L) / platelet (/L). The cut-off value was determined by examining the area under the receiver operating characteristic (ROC) curve for the SII value. The endpoints of this study included overall survival (OS) and progression-free survival (PFS). Results: A total of 168, patients who received ICI in the metastatic stage, were evaluated. The OS of the patients with low SII scores was 110.8 months (95% CI, 88.2-133.5), while patients with high SII scores were 36.0 months (95% CI, 28.4-43.6) and reached statistical significance (p <0.001). The results of univariate (HR=3.376, 95% CI, 1.986-5.739, p<0.001 and multivariate (HR=2.792, 95% CI, 1.495-5.215, p=0.011) analyses were statistically significant as well. Conclusion: The SII score in patients with metastatic disease receiving ICI was closely related to the prognosis. Patients with a high SII score are associated with a worse prognosis, these patients develop fewer irAEs. © 2022 College of Physicians and Surgeons Pakistan. All rights reserved.
dc.identifier.DOI-ID10.29271/jcpsp.2022.08.996
dc.identifier.issn1022386X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12648
dc.language.isoEnglish
dc.publisherCollege of Physicians and Surgeons Pakistan
dc.rightsAll Open Access; Gold Open Access
dc.subjectBiomarkers
dc.subjectCohort Studies
dc.subjectHumans
dc.subjectImmune Checkpoint Inhibitors
dc.subjectInflammation
dc.subjectLymphocytes
dc.subjectNeutrophils
dc.subjectPrognosis
dc.subjectRetrospective Studies
dc.subjectatezolizumab
dc.subjectimmune checkpoint inhibitor
dc.subjectipilimumab
dc.subjectnivolumab
dc.subjectpembrolizumab
dc.subjectprotein tyrosine kinase inhibitor
dc.subjectbiological marker
dc.subjectadjuvant therapy
dc.subjectadult
dc.subjectadverse event
dc.subjectaged
dc.subjectArticle
dc.subjectbone metastasis
dc.subjectbrain metastasis
dc.subjectcancer prognosis
dc.subjectcancer survival
dc.subjectcohort analysis
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjectimmune related adverse event
dc.subjectimmunotherapy
dc.subjectinflammation
dc.subjectliver metastasis
dc.subjectlung metastasis
dc.subjectlymphocyte count
dc.subjectmale
dc.subjectmetastasis
dc.subjectneutrophil count
dc.subjectoverall survival
dc.subjectplatelet count
dc.subjectprogression free survival
dc.subjectreceiver operating characteristic
dc.subjectrenal cell carcinoma
dc.subjectadverse event
dc.subjectinflammation
dc.subjectlymphocyte
dc.subjectneutrophil
dc.subjectpathology
dc.subjectprognosis
dc.subjectretrospective study
dc.titleSystemic Immune Inflammation Index as a Key Marker of Survival and Immune-related Adverse Events in Immune Checkpoint Inhibitor Therapy
dc.typeArticle

Files

Collections

Scopus Koleksiyonu